Fecal microbiota-based treatment for recurrent Clostridioides difficile infection

Jens Walter; Fergus Shanahan

doi:10.1016/j.cell.2023.02.034

Fecal microbiota-based treatment for recurrent Clostridioides difficile infection

Cell. 2023 Mar 16;186(6):1087. doi: 10.1016/j.cell.2023.02.034.

Authors

Jens Walter¹, Fergus Shanahan²

Affiliations

¹ APC Microbiome Ireland and Department of Medicine, University College Cork, Cork, Ireland; School of Microbiology, University College Cork, Cork, Ireland. Electronic address: jenswalter@ucc.ie.
² APC Microbiome Ireland and Department of Medicine, University College Cork, Cork, Ireland.

PMID: 36931236
DOI: 10.1016/j.cell.2023.02.034

Abstract

Rebyota is a rectally administered fecal microbiota suspension for prevention of recurrence of Clostridioides difficile infection. The mechanism of action of Rebyota probably involves competitive exclusion of C. difficile by donor microbes with reduced toxin production; other factors may include restoration of protective taxa and modulation of the recipient's microbiome by phage, donor microbes, or metabolites.

MeSH terms

Clostridioides difficile*
Clostridium Infections* / therapy
Fecal Microbiota Transplantation
Feces
Humans
Microbiota*
Recurrence